Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0 Study of the Pharmacokinetics and Biodistribution of PSMA-Targeted [In-111]-Labeled Trillium Compounds With and Without PTI-122 in Patients With Metastatic Prostate Cancer to Inform Future Phase 1 Dosing With [Ac-225]-Trillium-PSMA Radionuclide Therapy

NCT05773703 is registered in ClinicalTrials.gov with Ratio Therapeutics, Inc. as lead sponsor.

NCT NCT05773703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05773703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0 Study of the Pharmacokinetics and Biodistribution of PSMA-Targeted [In-111]-Labeled Trillium Compounds With and Without PTI-122 in Patients With Metastatic Prostate Cancer to Inform Future Phase 1 Dosing With [Ac-225]-Trillium-PSMA Radionuclide Therapy
Lead sponsor
Ratio Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 8, 2022
Completion date
December 12, 2023
Enrollment
23 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer